Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
50M
-
Number of holders
-
88
-
Total 13F shares, excl. options
-
33.8M
-
Shares change
-
+8.27M
-
Total reported value, excl. options
-
$229M
-
Value change
-
+$23.5M
-
Put/Call ratio
-
0.09
-
Number of buys
-
48
-
Number of sells
-
-46
-
Price
-
$6.76
Significant Holders of KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (KALV) as of Q4 2022
114 filings reported holding KALV - KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q4 2022.
KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (KALV) has 88 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.8M shares
of 50M outstanding shares and own 67.61% of the company stock.
Largest 10 shareholders include TCG Crossover Management, LLC (3.4M shares), Frazier Life Sciences Management, L.P. (3.24M shares), TANG CAPITAL MANAGEMENT LLC (3.2M shares), VR Adviser, LLC (2.92M shares), BlackRock Inc. (1.57M shares), FMR LLC (1.31M shares), Jefferies Financial Group Inc. (1.2M shares), VANGUARD GROUP INC (1.15M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (1.07M shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (1.06M shares).
This table shows the top 88 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.